Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis

Model scores of the 29,894 trials active now.

Model score 30% for any early termination, 15% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2018-01-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: screeningprior todoubleto determineentry
  Phrases that lowered it: patientsmoderatedrugsseveredisorder
• Accepts healthy volunteers: No (raises risk) · Who can join
• Disease area, cancer: Yes (raises risk) · Disease area
• Phase: 2 (raises risk) · Design
• Responsible party: sponsor investigator (raises risk) · Design
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
• Design: single group (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Disease area, neurology: Yes (raises risk) · Disease area
• Minimum age: 18 (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Number of arms: 1 (raises risk) · Design
• Drug's FAERS reports marked serious: 92.2% (raises risk) · Drug's FDA history
• Drug's FAERS reports before start: 1945 (raises risk) · Drug's FDA history
• Collaborators: 1 (raises risk) · Design
• Blinding: none (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis NCT01828294 · started 2011 · scored riskier than 52% of active trials terminated
• A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis NCT02473952 · started 2015 · scored riskier than 78% of active trials completed
• Evaluate the Efficacy and Safety of HBM9161(HL161)Subcutaneous Injection in Patients With Generalized MG Patients NCT05039190 · started 2021 · scored riskier than 24% of active trials completed
• A Pilot Trial To Assess The Feasibility And Efficacy Of SCIG In Patients With MG Exacerbation (SCIG-MG) NCT02774239 · started 2014 · scored riskier than 41% of active trials completed
• A Study to Assess the Efficacy and Safety of IGIV-C in Patients With Myasthenia Gravis Exacerbations NCT02413580 · started 2015 · scored riskier than 57% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.